HPV and the Future of Cervical Screening

Size: px
Start display at page:

Download "HPV and the Future of Cervical Screening"

Transcription

1 HPV and the Future of Cervical Screening John Tidy, Professor of Gynaecological Oncology Chair, National Colposcopy QA Committee, Sheffield

2 What is HPV? Small ds DNA virus Over 140 genotypes described Restricted infection Only certain types of HPV can infected certain tissues HPVs 1 and 2 affect skin of hand and foot HPVs 6,11,16 and 18 infect genital and oral mucosa

3 What is HPV? Cannot be cultured in the laboratory Detected only tests for HPV DNA or RNA 80% of people become infected with HPV after on set of sexual activity HPV is transmitted by intimate contact Most people eradicate HPV infection but can take over 13 months Persistence of HPV infection linked to the development of cervical neoplasia

4 HPV Vaccination Now using Gardasil (HPV 6,11,16 &18) From September doses, at least 6 months apart Year 8 (12-13 year old girls) Uptake 2013/14 287,757 girls Dose % ( %) Dose % ( %) All 3 doses 79.7% ( %)

5 HPV Vaccination Recent results from a 9-valent HPV vaccine HPVs 6,11,16,18,31,33,45,52 and 58 HPV 31,33,45,52 and 58 related disease 0.1 per 1000 person years in 9-valent group 1.6 per 1000 person years in HPV 6,11,16 and 18 group Adverse events related to injection site more common in 9-valent group Joura et al 2015

6 Effect of HPV Vaccination Data from Scotland Still commence screening from age 20 Commenced HPV vaccination in 2008 School based (80%) and catch-up (30%) Linked data sets from screening programme and colposcopy records fro women aged in Reduction in rates of CIN for vaccinated population CIN3 RR 0.45, CIN2 RR 0.5, CIN1 RR 0.7 Pollock et al 2014

7 How is HPV testing used in the current English Cervical Screening Programme Utilise the high sensitivity and negative predictive value of HPV testing In excess of 98% of all high grade cervical neoplasia (CIN2+) and invasive cancers contain high risk HPV (HR-HPV) The absence of HR-HPV predicts the absence of cervical neoplasia

8 Two stage evaluation of HR-HPV testing Evaluation within an effective organised quality assured national screening programme HR-HPV testing for triage of low grade dyskaryosis (borderline, mild) Test of cure 6 months after treatment for CIN HR-HPV testing as primary screen with reflex cytology

9 Why use HR-HPV testing in triage of low grade cytology Increased detection of high grade CIN leading to earlier treatment and early discharge Early return of women with low grade cytology who were HR-HPV negative to routine recall Early return of women with low grade cytology and are HR-HPV positive but have a negative satisfactory colposcopy to routine recall

10 Why use HR-HPV testing in triage of low grade cytology Cost effectiveness Despite increased costs of HR-HPV testing and temporary increase in colposcopy workload there are savings made from reducing community based cytology follow up samples Cost effectiveness for triage of mild dyskaryosis may appear not be significant for an individual laboratory but will be effective for the NHSCSP

11 Rationale for HPV Sentinel Site Study Insufficient data from LBC/HPV triage pilots Need to assess HR-HPV testing as part of test of cure Comparative data between Thinprep and Surepath LBC systems Using residuum for HR-HPV testing Establish cut off for HR-HPV testing by HC2 Used 2RLU as positive and NOT 1RLU

12 Rationale for HPV Sentinel Site Six centres Study Manchester, Liverpool, Sheffield, Norwich, Northwick Park and Bristol Four centres Thinprep Manchester, Norwich, Northwick Park and Bristol Three centres Surepath Manchester, Liverpool, Sheffield, Two centre for HPV testing Manchester and Bristol

13 BORDERLINE or MILD DYSKARYOSIS Moderate dyskaryosis or worse with treated CIN HPV -ve HPV +ve COLPOSCOPY No repeat cytology BORDERLINE/MILD with negative colposcopy, no biopsy or biopsy with no CIN CIN1 CIN2/3 No treatment TREATMENT Cytology at 12 months with or without colposcopy Cytology only at 6 months Normal, borderline, mild Moderate, severe HPV ve HPV +ve Routine 3 or 5 year recall (depending on age <50 or 50) 3 year recall COLPOSCOPY Treat or, if normal, cytology follow up according to national

14 Results from the Sentinel Site Study

15 Sentinel sites HR-HPV +ve (%) rates by cytology and age Borderline Mild Total Age group N=6507 N=3544 N= N= N= N=815 Total N= % 89.2% 77.2% 41.9% 77.0% 52.0% 31.0% 66.5% 40.2% 53.7% 83.9% 64.4%

16 Percentage HR-HPV positivity in borderline cytology and PPV for high grade CIN A B C D E F Study site Borderline HPV% Borderline PPV CIN2+ Borderline PPV CIN3+ Av. CIN3 6.7%

17 Percentage HR-HPV positivity in mild cytology and PPV for high grade CIN Mild HPV% Mild PPV CIN2+ Mild PPV CIN3+ Av. CIN3 5.4% A B C D E F Study site

18 Use of HPV as a Test of Cure The absence of HPV 6 months treatment in women with negative or low grade cytology predicts the absence of residual disease Women can be discharged to 3 yearly recall The presence of HPV 6 months treatment in women with negative or low grade cytology increases the detection of residual disease

19 Detection of CIN in Test of Cure overall data PPV to detect CIN CIN2+ CIN3+ Abnormal cytology 13.3% 8.1% Normal cytology / HPV+ 2.7% 0.4% The incidence of CIN in the normal cytology/hpv + group is very low Discharge this group to routine recall

20 Summary HR-HPV triage reduces the need for follow up cytology in Borderline 3.8% of all smears (127,367) Mild dyskaryosis 2.2% of all smears (74,757) Must have three negative samples before returning to routine recall Borderline HR-HPV ve 46.3% Mild dyskaryosis HR-HPV ve 16.1%

21 Summary HR-HPV triage allows early diagnosis and treatment of high grade CIN and early return of women without CIN to routine recall Borderline CIN % Colp neg +/- neg Bx 45.53% Mild dyskaryosis CIN % Colp neg +/- neg Bx 37.10%

22 Summary Addition of HR-HPV for test of cure allows women who have been treated for CIN to return to routine recall so avoid need for 7 extra cytology samples (10 annual 3x3 yearly recall) 80.6% of all women treated for CIN will be cytology negative / HR-HPV negative so can be returned to routine recall

23 HPV testing as a Primary Screen Increased sensitivity of HPV testing may increase disease detection The absence of HPV may allow screening interval to be increased Screening with cytology may not be fit for purpose in a vaccinated population with low prevalence of disease

24 English NHS Cervical Screening Programme HPV Primary Screening Sentinel Site Study Coverage of 140,000 screened women Commenced mid April 2013 Invitations sent out Roll out at each of the sites over the following 6 weeks Extensive web based information and training packages for primary care

25 Primary HPV Screening Assessment of HPV genotyping Assessment of CINTEC plus Assessment of colposcopic performance by HPV genotyping

26 Primary HPV Screening 6 sites all previously part of sentinel site study Local models for conversion to primary HPV screening are variable Single PCT or GP practices across PCTs Bristol Liverpool Manchester Norfolk and Norwich Northwick Park Sheffield

27 Primary HPV Screening Different HPV technologies will be used at each site Roche Norfolk and Norwich, Sheffield Genprobe Bristol,Liverpool Abbot Manchester, Northwick Park Comparison studies between HC2 and other technologies At least 400 samples dual tested Good agreement between HC2 and other technologies

28 HPV Primary Screening Algorithm Pilot Year 1 All women aged on routine call/recall and early recall HR-HPV Test HR-HPV -ve Routine recall 3y(25-49) 5y( 50)* HR-HPV +ve Cytology triage Cytology normal # Cytology abnormal borderline or worse Re-screen in 12m Colposcopy referral HR-HPV -ve HR-HPV +ve Routine recall 3y(25-49) 5y( 50)* Cytology normal # Cytology abnormal borderline or worse Notes Inadequate tests at any screening episode in the pathway will be repeated in 3 months. Three inadequate tests in a row will lead to a colposcopy referral. Women in follow up for cgin, SMILE or microinvasive carcinoma at a pilot site will be given annual HPV testing (instead of cytology) for 10 years. *Routine recall to be extended to 6 years (subject to approval) for all age groups entering pilot in year 2. #HPV16/18 recorded where available. Final Version 1.0 February 2013 Re-screen in 12m HR-HPV -ve Routine recall 3y(25-49) 5y( 50)* Colposcopy referral HR-HPV +ve # Colposcopy referral

29 HPV Primary Screening Pilot Colposcopy Management Recommendations Colposcopy Examination Inadequate Normal and adequate Abnormal Index test HR- HPV +ve/cytology low grade <40yrs Index HR-HPV +ve/cytology high grade or 40yrs No biopsy or biopsy <CIN1 Abnormal Biopsy CIN1+ CIN1 CIN2 Negative biopsy Repeat colposcopy in 12m LLETZ Index test HR-HPV +ve/ cytology low grade Index test HR-HPV +ve/cytology high grade Recall in 12m Manage according to national guidance Discussion at MDT within 2m Discharge to 3y recall Discussion at MDT within 2m HR-HPV -ve HR-HPV +ve Version 1.1 December y recall Cytology negative 12m recall Cytology abnormal Refer to colposcopy

30 The story so far Sheffield May 2013 Norfolk and Norwich May 2013 Liverpool July 2013 Manchester July 2013 Bristol September 2013

31 The story so far HPV positivity rate % HPV positive / negative cytology rate % Referral to colposcopy rate %

32 Conclusions Evaluation of primary HR-HPV testing with reflex cytology has commenced HR-HPV positivity rates are as expected Better rates of HR-HPV positive/cytology negative compared with ARTISTIC Referral rates to colposcopy unchanged at 4% of the screened population Referral rates may increase due to persistence of HPV infection

33

Dr Julia Palmer BAC Annual Scientific Meeting October 2015 THE IMPACT OF HPV PRIMARY SCREENING ON COLPOSCOPY.

Dr Julia Palmer BAC Annual Scientific Meeting October 2015 THE IMPACT OF HPV PRIMARY SCREENING ON COLPOSCOPY. Dr Julia Palmer BAC Annual Scientific Meeting October 2015 THE IMPACT OF HPV PRIMARY SCREENING ON COLPOSCOPY. Aims: An evaluation of primary HPV screening commenced in Sheffield in May 2013. This lecture

More information

Appendix 1. HPVTest of Cure Management

Appendix 1. HPVTest of Cure Management Appendix 1. HPVTest of Cure Management 6 months post treatment cervical smear and HPV test 1. Smear negative or squamous. HPV negative 2. Smear negative, squamous, glandular or unsatisfactory. HPV positive

More information

Cervical Screening Programme

Cervical Screening Programme Cervical Screening Programme England 2010-11 1 The NHS Information Centre is England s central, authoritative source of health and social care information. Acting as a hub for high quality, national, comparative

More information

NHS Cervical Screening Programme. HPV Triage and Test of Cure Implementation Guide

NHS Cervical Screening Programme. HPV Triage and Test of Cure Implementation Guide NHS Cervical Screening Programme HPV Triage and Test of Cure Implementation Guide NHSCSP GOOD PRACTICE GUIDE NUMBER 3 JULY 2011 HPV TRIAGE AND TEST OF CURE: IMPLEMENTATION GUIDANCE NHSCSP Good Practice

More information

Colposcopy and Programme Management. Guidelines for the NHS Cervical Screening Programme Second edition

Colposcopy and Programme Management. Guidelines for the NHS Cervical Screening Programme Second edition Colposcopy and Programme Management Guidelines for the NHS Cervical Screening Programme Second edition NHSCSP Publication No 20 May 2010 Second Edition Editors David Luesley, Simon Leeson Editorial Group

More information

NATIONAL GUIDELINE FOR CERVICAL CANCER SCREENING PROGRAMME

NATIONAL GUIDELINE FOR CERVICAL CANCER SCREENING PROGRAMME NATIONAL GUIDELINE FOR CERVICAL CANCER SCREENING PROGRAMME CERVICAL CANCER Introduction Cancer of the cervix is the second most common form of cancer amongst South African women. Approximately one in every

More information

Management of Abnormal PAP Smears. K Chacko, MD, FACP 2010 GIM Conference

Management of Abnormal PAP Smears. K Chacko, MD, FACP 2010 GIM Conference Management of Abnormal PAP Smears K Chacko, MD, FACP 2010 GIM Conference Scope of the Problem About 7-10% 7 of PAPs will come back abnormal 3.5 to 4 million in the US each year Approximate 4000 deaths

More information

NHS Cervical Screening Programme Achievable standards, Benchmarks for reporting, and Criteria for evaluating cervical cytopathology

NHS Cervical Screening Programme Achievable standards, Benchmarks for reporting, and Criteria for evaluating cervical cytopathology NHS Cervical Screening Programme Achievable standards, Benchmarks for reporting, and Criteria for evaluating cervical cytopathology third edition including revised performance indicators NHSCSP PubliCatioN

More information

Cervical Cancer Screening and Management Guidelines: Changing Again, Huh?

Cervical Cancer Screening and Management Guidelines: Changing Again, Huh? Cervical Cancer Screening and Management Guidelines: Changing Again, Huh? Summary of 2013 recommendations from ASC (American Cancer Society), ASCCP (American Society for Colposcopy and Cervical Pathology),

More information

TAKING SAMPLES FOR CERVICAL SCREENING. A Resource Pack for Trainers

TAKING SAMPLES FOR CERVICAL SCREENING. A Resource Pack for Trainers TAKING SAMPLES FOR CERVICAL SCREENING A Resource Pack for Trainers NHSCSP Publication No 23 April 2006 Published by: NHS Cancer Screening Programmes Fulwood House Old Fulwood Road Sheffield S10 3TH Tel:

More information

NHS cervical screening Helping you decide

NHS cervical screening Helping you decide NHS cervical screening Helping you decide What is cervical cancer? 2 What causes cervical cancer? 2 What is cervical screening? 3 Cervical screening results 6 What is a colposcopy? 8 What are the benefits

More information

GLOBAL CONCERNS ABOUT HPV VACCINES FACT SHEET

GLOBAL CONCERNS ABOUT HPV VACCINES FACT SHEET GLOBAL CONCERNS ABOUT HPV VACCINES FACT SHEET When detected, HPV infection is easily managed and rarely proceeds to cancer Very few women with HPV develop cervical cancer HPV infections are only one of

More information

Cervical Cancer The Importance of Cervical Screening and Vaccination

Cervical Cancer The Importance of Cervical Screening and Vaccination Cervical Cancer The Importance of Cervical Screening and Vaccination Cancer Cells Cancer begins in cells, the building blocks that make up tissues. Tissues make up the organs of the body. Sometimes, this

More information

Further investigations, treatments and new technologies

Further investigations, treatments and new technologies Promoting Cervical Screening Information for Health Professionals Further investigations, treatments and new technologies Population Health Queensland Cancer Screening Services Branch Queensland Cervical

More information

GUIDELINE DOCUMENT CERVICAL CANCER SCREENING IN SOUTH AFRICA 2015

GUIDELINE DOCUMENT CERVICAL CANCER SCREENING IN SOUTH AFRICA 2015 GUIDELINE DOCUMENT CERVICAL CANCER SCREENING IN SOUTH AFRICA 2015 Cervical cancer remains an important cause of morbidity and mortality in South Africa. At present the national cervical cancer prevention

More information

American Academy of Family Physicians

American Academy of Family Physicians American Academy of Family Physicians Barbara E. Stanford MD Grand Rapids Family Medicine Residency Wege Family Medicine HPV is transient in most women HPV-75% Normal ASCUS LSIL HSIL Cancer 80-90% 75%???

More information

Examples of good screening tests include: mammography for breast cancer screening and Pap smears for cervical cancer screening.

Examples of good screening tests include: mammography for breast cancer screening and Pap smears for cervical cancer screening. CANCER SCREENING Dr. Tracy Sexton (updated July 2010) What is screening? Screening is the identification of asymptomatic disease or risk factors by history taking, physical examination, laboratory tests

More information

The link between cervical cancer and HPV (human papillomavirus)

The link between cervical cancer and HPV (human papillomavirus) The link between cervical cancer and HPV (human papillomavirus) The link between cervical cancer and HPV Key facts: HPV is a virus (the human papillomavirus). Almost all abnormal Pap smear results are

More information

Clinical Practice Guidance for the Assessment of Young Women aged 20-24 with Abnormal Vaginal Bleeding

Clinical Practice Guidance for the Assessment of Young Women aged 20-24 with Abnormal Vaginal Bleeding Clinical Practice Guidance for the Assessment of Young Women aged 20-24 with Abnormal Vaginal Bleeding Clinical Practice Guidance for the Assessment of Young Women aged 20-24 with Abnormal Vaginal Bleeding

More information

HPV testing in the follow-up of women post colposcopy treatment

HPV testing in the follow-up of women post colposcopy treatment HPV testing in the follow-up of women post colposcopy treatment Contents Background 2 Treatment of CIN and risk of recurrence 2 The natural history of HPV infections 2 HPV testing for women following

More information

NHS Cervical Screening Having a colposcopy

NHS Cervical Screening Having a colposcopy NHS Cervical Screening Having a colposcopy What is a colposcopy? 1 Why do I need a colposcopy? 1 What does a colposcopy involve? 2 Colposcopy results 4 Treatment to remove abnormal cells in the cervix

More information

XI International Workshop of Lower Genital Tract Pathology HPV Disease: The global battle Rome 19-21 April 2012

XI International Workshop of Lower Genital Tract Pathology HPV Disease: The global battle Rome 19-21 April 2012 XI International Workshop of Lower Genital Tract Pathology HPV Disease: The global battle Rome 19-21 April 2012 Thursday 19 nd April 2012 Morning Sessions 07.50-08.20 Registration 08.20-08.40 Welcome:

More information

Cervical Screening and HPV Vaccine Guidelines In Saudi Arabia. Prof. Mohammed Addar Chairmen Gyneoncology section KKUH, King Saud University

Cervical Screening and HPV Vaccine Guidelines In Saudi Arabia. Prof. Mohammed Addar Chairmen Gyneoncology section KKUH, King Saud University Cervical Screening and HPV Vaccine Guidelines In Saudi Arabia Prof. Mohammed Addar Chairmen Gyneoncology section KKUH, King Saud University Burden of HPV related cancers l l Cervical Cancer of the cervix

More information

HPV OncoTect E6, E7 mrna Kit A highly specific molecular test for early detection of cervical cancer

HPV OncoTect E6, E7 mrna Kit A highly specific molecular test for early detection of cervical cancer Revolutionizing healthcare one cell at a time HPV OncoTect E6, E7 mrna Kit A highly specific molecular test for early detection of cervical cancer Numerous studies confirm that the presence of HR HPV DNA

More information

Biomedical Engineering for Global Health. Lecture Thirteen

Biomedical Engineering for Global Health. Lecture Thirteen Biomedical Engineering for Global Health Lecture Thirteen Outline The burden of cancer How does cancer develop? Why is early detection so important? Strategies for early detection Example cancers/technologies

More information

Explanation of your PAP smear

Explanation of your PAP smear Explanation of your PAP smear Approximately 5-10% of PAP smears in the United States are judged to be abnormal. Too often, the woman who receives this news worries that she already has, or will develop,

More information

CXCA-MSP. The next step in cervical cancer prevention! GynTect : Epigenetic biomarkers for reliable cancer diagnostics. www.gbo.

CXCA-MSP. The next step in cervical cancer prevention! GynTect : Epigenetic biomarkers for reliable cancer diagnostics. www.gbo. CXCA-MSP The next step in cervical cancer prevention! GynTect : Epigenetic biomarkers for reliable cancer diagnostics www.gbo.com/diagnostics H 3 C NH 2 NH H 3 C 2 N mc N mc N H N O H O The challenge of

More information

HEALTH TECHNOLOGY ASSESSMENT

HEALTH TECHNOLOGY ASSESSMENT HEALTH TECHNOLOGY ASSESSMENT VOLUME 18 ISSUE 23 APRIL 2014 ISSN 1366-5278 The clinical effectiveness and cost-effectiveness of primary human papillomavirus cervical screening in England: extended follow-up

More information

Impact of organized primary HPV-screening

Impact of organized primary HPV-screening Impact of organized primary HPV-screening Pekka Nieminen, M.D., Ph.D Associate Professor, Chief Physician Dept. of Obstetrics & Gynecology Helsinki University Central Hospital Prevention of cervical cancer

More information

Colposcopy. Information for patients. Women s & Children s

Colposcopy. Information for patients. Women s & Children s Women s & Children s Colposcopy Information for patients Welcome to the gynaecology service at King s. The Colposcopy Unit is situated in Suite 8 of the Golden Jubilee Wing. The information in this leaflet

More information

Cervical Cancer Screening. Clinical Practice Guidelines for Average Risk Women

Cervical Cancer Screening. Clinical Practice Guidelines for Average Risk Women QEYGYN051 Cervical Cancer Screening Clinical Practice Guidelines for Average Risk Women For Approval of the Provincial Medical Affairs Committee October 2013 Table of Contents Page Background Information

More information

Making Sense of Your Pap and HPV Test Results

Making Sense of Your Pap and HPV Test Results Making Sense of Your Pap and HPV Test Results Keep this booklet until you get your test results back from your doctor. U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES Centers for Disease Control and Prevention

More information

Media Contacts: Annick Robinson Investor Contacts: Justin Holko (438) 837-2550 (908) 740-1879 annick.robinson@merck.com

Media Contacts: Annick Robinson Investor Contacts: Justin Holko (438) 837-2550 (908) 740-1879 annick.robinson@merck.com News Release FOR IMMEDIATE RELEASE Media Contacts: Annick Robinson Investor Contacts: Justin Holko (438) 837-2550 (908) 740-1879 annick.robinson@merck.com Merck's HPV Vaccine, GARDASIL 9, now available

More information

Summary of Key Points WHO Position Paper on Vaccines against Human Papillomavirus (HPV) October 2014

Summary of Key Points WHO Position Paper on Vaccines against Human Papillomavirus (HPV) October 2014 Summary of Key Points WHO Position Paper on Vaccines against Human Papillomavirus (HPV) October 2014 1 Background l Selected types of HPV cause cervical cancer, anogenital warts, and other anogenital and

More information

HPV is very common and usually clears up on its own

HPV is very common and usually clears up on its own What is HPV? All cervical cancers are linked to a very common virus called the human papillomavirus or HPV. HPV usually doesn t cause any harm and most people will be infected with it at some point in

More information

An abnormal Pap smear - what does it mean?

An abnormal Pap smear - what does it mean? An abnormal Pap smear - what does it mean? It is natural to feel worried if you have just found out that your Pap smear result is not normal (abnormal). Around 1 in 10 Pap smears will show changes in the

More information

Pap smears, cytology and CCHC lab work and follow up

Pap smears, cytology and CCHC lab work and follow up Pap smears, cytology and CCHC lab work and follow up What is a Pap Smear? A Pap smear (also known as the Pap test) is a medical procedure in which a sample of cells from a woman's cervix (the end of the

More information

Accent on Health Obgyn, PC HPV Frequently Asked Questions

Accent on Health Obgyn, PC HPV Frequently Asked Questions 1. What is HPV? 2. How do you get HPV? 3. How common is HPV? 4. What are the symptoms of HPV? 5. Can HPV be treated? 6. What is the HPV test and how is it different from a PAP test? 7. Can the HPV test

More information

Improving equality of access to cervical screening

Improving equality of access to cervical screening Summary Improving equality of access to cervical screening Karen Gribben and Michelle Bell examine the literature on why women with a learning disability are not attending for smear tests and missing out

More information

Cancer Screening Programmes CERVICAL SCREENING. The Colposcopy Examination

Cancer Screening Programmes CERVICAL SCREENING. The Colposcopy Examination Cancer Screening Programmes CERVICAL SCREENING The Colposcopy Examination You have been asked to come for a colposcopy examination. Why do I need a further examination? 2 You have been asked to come for

More information

Cervical cancer is the second most common cancer among South African women

Cervical cancer is the second most common cancer among South African women Cervical cancer is the second most common cancer among South African women *SA Statistics as per National Cancer Registry (NCR) 2007 What is cervical cancer? Cervical cancer is a type of cancer that occurs

More information

4/30/2013 HPV VACCINE AND NORTH DAKOTA HPV IMMUNIZATION RATES HUMAN PAPILLOMAVIRUS (HPV) HUMAN PAPILLOMAVIRUS HPV CONTINUED

4/30/2013 HPV VACCINE AND NORTH DAKOTA HPV IMMUNIZATION RATES HUMAN PAPILLOMAVIRUS (HPV) HUMAN PAPILLOMAVIRUS HPV CONTINUED HPV VACCINE AND NORTH DAKOTA HPV IMMUNIZATION RATES HUMAN PAPILLOMAVIRUS (HPV) HUMAN PAPILLOMAVIRUS What is human papillomavirus (HPV)? HPV is the most common sexually transmitted infection. There are

More information

Pre test Question 2. Emily D. Babcock, DHSc, PA C, DFAAPA CAPA Annual Conference Palm Springs, California October 4, 2013

Pre test Question 2. Emily D. Babcock, DHSc, PA C, DFAAPA CAPA Annual Conference Palm Springs, California October 4, 2013 Emily D. Babcock, DHSc, PA C, DFAAPA CAPA Annual Conference Palm Springs, California October 4, 2013 Objectives After completion of this presentation, the participant will be able to: Explain the current

More information

Cervical cancer screening with the HPV test and the Pap test in women ages 30 and older

Cervical cancer screening with the HPV test and the Pap test in women ages 30 and older Cervical cancer screening with the HPV test and the Pap test in women ages 30 and older When to get tested and how to make sense of your test results If you are 30 years or older and your Pap test is normal

More information

Cervical Cancer Screening Guideline

Cervical Cancer Screening Guideline Cervical Cancer Screening Guideline Prevention 2 Abbreviations Used 2 Specimen Collection Techniques 3 Screening 4 Management Women 21 Years and Older Pap results 5 findings: ASC-US and LSIL 6 findings:

More information

NATIONAL STATISTICS TO MONITOR THE NHS CANCER PLAN - REPORT OF A PRE SCOPING STUDY

NATIONAL STATISTICS TO MONITOR THE NHS CANCER PLAN - REPORT OF A PRE SCOPING STUDY NATIONAL STATISTICS TO MONITOR THE NHS CANCER PLAN - REPORT OF A PRE SCOPING STUDY Statistics Commission Report No 2 May Statistics Commission Statistics Commission Report No. 2 National Statistics to

More information

Genital Human Papillomavirus. Patti E. Gravitt, PhD Johns Hopkins University

Genital Human Papillomavirus. Patti E. Gravitt, PhD Johns Hopkins University This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike License. Your use of this material constitutes acceptance of that license and the conditions of use of materials on this

More information

Cancer of the Cervix

Cancer of the Cervix Cancer of the Cervix WOMENCARE A Healthy Woman is a Powerful Woman (407) 898-1500 A woman's cervix (the opening of the uterus) is lined with cells. Cancer of the cervix occurs when those cells change,

More information

Preventing Cervical Cancer with Gardasil Jana Ogden RN, MSN, MBA-HCA, IHCC Nursing Faculty. Upon Completion of the Lesson the student will be able to:

Preventing Cervical Cancer with Gardasil Jana Ogden RN, MSN, MBA-HCA, IHCC Nursing Faculty. Upon Completion of the Lesson the student will be able to: Preventing Cervical Cancer with Gardasil Jana Ogden RN, MSN, MBA-HCA, IHCC Nursing Faculty Upon Completion of the Lesson the student will be able to: Review statistics related to cervical cancer and HPV

More information

Guidelines for. Quality Assurance in Cervical Screening. Second Edition

Guidelines for. Quality Assurance in Cervical Screening. Second Edition Guidelines for Assurance in Cervical Screening Second Edition Chapter 2 assurance in programme operation 2.1 Introduction 2.2 assurance s and standards 2.2.1 Screening population and screening intervals

More information

PROPERTY OF ELSEVIER SAMPLE CONTENT - NOT FINAL ABNORMAL PAP SMEAR (ABNORMAL CERVICAL CYTOLOGIC FINDINGS) Kathleen Dor

PROPERTY OF ELSEVIER SAMPLE CONTENT - NOT FINAL ABNORMAL PAP SMEAR (ABNORMAL CERVICAL CYTOLOGIC FINDINGS) Kathleen Dor 1 ABNORMAL PAP SMEAR (ABNORMAL CERVICAL CYTOLOGIC FINDINGS) Kathleen Dor Cervical cytology screening has significantly decreased rates of mortality from cervical cancer; however, 400 women die each year

More information

The society for lower genital tract disorders since 1964.

The society for lower genital tract disorders since 1964. The society for lower genital tract disorders since 1964. Updated Consensus Guidelines for Managing Abnormal Cervical Cancer Screening Tests and Cancer Precursors American Society for and Cervical Pathology

More information

Preventive Care Guideline for Asymptomatic Low Risk Adults Age 18 through 64

Preventive Care Guideline for Asymptomatic Low Risk Adults Age 18 through 64 Preventive Care Guideline for Asymptomatic Low Risk Adults Age 18 through 64 1. BMI - Documented in patients medical record on an annual basis. Screen for obesity and offer intensive counseling and behavioral

More information

Main Changes to the Vaccination Schedule Recommended by the Japan Pediatric Society January 12, 2014

Main Changes to the Vaccination Schedule Recommended by the Japan Pediatric Society January 12, 2014 Main Changes to the Vaccination Schedule Recommended by the Japan Pediatric Society January, 04 ) 3-valent Pneumococcal conjugate vaccine (PCV3) The description of catch-up schedule for PCV3 has been revised

More information

Immunization Healthcare Branch. Human Papillomavirus Vaccination Program Questions and Answers. Prepared by

Immunization Healthcare Branch. Human Papillomavirus Vaccination Program Questions and Answers. Prepared by Immunization Healthcare Branch Human Papillomavirus Vaccination Program Questions and Answers Prepared by Immunization Healthcare Branch (IHB), Defense Health Agency Last Updated: 02 Jan 14 www.vaccines.mil

More information

HUMAN PAPILLOMAVIRUS (HPV) FACT SHEET

HUMAN PAPILLOMAVIRUS (HPV) FACT SHEET HUMAN PAPILLOMAVIRUS (HPV) FACT SHEET Background Information - Human Papillomavirus HPV is the name of a group of viruses that include more than 80 different types associated with a variety of epidermal

More information

Clinical Indicator Ages 19-29 Ages 30-39 Ages 40-49 Ages 50-64 Ages 65+ Frequency of visit as recommended by PCP

Clinical Indicator Ages 19-29 Ages 30-39 Ages 40-49 Ages 50-64 Ages 65+ Frequency of visit as recommended by PCP SCREENING EXAMINATION & COUNSELING UPMC Health Plan Clinical Indicator Ages 19-29 Ages 30-39 Ages 40-49 Ages 50-64 Ages 65+ Annually Physical Exam and Counseling 1 Blood Pressure 2 At each visit. At least

More information

Ten Good Reasons to Be Concerned about the Human Papillomavirus (HPV) Vaccination Campaign

Ten Good Reasons to Be Concerned about the Human Papillomavirus (HPV) Vaccination Campaign Ten Good Reasons to Be Concerned about the Human Papillomavirus (HPV) Vaccination Campaign This document is a translation and adaption of an information brochure prepared by the Federation du Québec pour

More information

Cervical Cancer. Cervical smear test. The cervix. Dysplasia. Cervical cancer. The female reproductive system

Cervical Cancer. Cervical smear test. The cervix. Dysplasia. Cervical cancer. The female reproductive system INFORMATION SHEET Cervical Cancer This information sheet has been written to provide you with information about cervical cancer (cancer of the cervix). The sheet has information about the different types

More information

Cervical Cancer. What you should know. making cancer less frightening by enlightening

Cervical Cancer. What you should know. making cancer less frightening by enlightening Cervical Cancer What you should know making cancer less frightening by enlightening cervical cancer the facts Around 325 women are diagnosed with cervical cancer in Ireland each year It is the most common

More information

HPV, Cervical Dysplasia and Cancer

HPV, Cervical Dysplasia and Cancer FACTSHEET HPV, Cervical Dysplasia and Cancer Summary Cervical dysplasia is an abnormal change in the cells of the cervix in the uterus. Early changes, called low-grade lesions by doctors, may persist and

More information

The Robert Darbishire Practice JOB DESCRIPTION. Nursing Team Leader

The Robert Darbishire Practice JOB DESCRIPTION. Nursing Team Leader The Robert Darbishire Practice JOB DESCRIPTION Nursing Team Leader JOB SUMMARY To provide a practice nursing service to patients, including in chronic disease management and other specialist areas. To

More information

Cervical screening. RCN guidance for good practice

Cervical screening. RCN guidance for good practice Cervical screening RCN guidance for good practice Supported by an educational grant from GlaxoSmithKline. GSK has not had any input into the content of this material. C E R V I C A L S C R E E N I N G

More information

Liquid-based cytology

Liquid-based cytology Liquid-based cytology Claire Bourgain UZBrussel Introduction LBC for gynaecological cytology has been introduced in Belgium a decade ago There is no consensus On performance compared to conventional cytology

More information

Vaccinating Every Adolescent Patient. Adjunct Professor of Family Medicine University of Minnesota at Mankato

Vaccinating Every Adolescent Patient. Adjunct Professor of Family Medicine University of Minnesota at Mankato Vaccinating Every Adolescent Patient Vince LaPorte LaPorte, MD Adjunct Professor of Family Medicine University of Minnesota at Mankato Funded by the Centers for Disease Control and Prevention via the Prevention

More information

Sage Screening Program. Provider Manual

Sage Screening Program. Provider Manual Sage Screening Program Provider Manual Sage Screening Program Minnesota Department of Health 85 E. 7th Place, Suite 400 P.O. Box 64882 St. Paul, Minnesota 55164-0882 (651) 201-5600 (phone) (651) 201-5601-

More information

HPV Vaccines. What is HPV? Can a vaccine help prevent HPV?

HPV Vaccines. What is HPV? Can a vaccine help prevent HPV? What is HPV? HPV Vaccines HPV stands for human papilloma virus. HPVs are a group of more than 150 related viruses. Each HPV virus in the group is given a number, and is called an HPV type (for instance,

More information

CONSOLIDATED GUIDANCE ON STANDARDS FOR THE NHS BREAST SCREENING PROGRAMME

CONSOLIDATED GUIDANCE ON STANDARDS FOR THE NHS BREAST SCREENING PROGRAMME CONSOLIDATED GUIDANCE ON STANDARDS FOR THE NHS BREAST SCREENING PROGRAMME NHSBSP Publication No 60 (Version 2) April 2005 Published by: NHS Cancer Screening Programmes The Manor House 260 Ecclesall Road

More information

Breast and Cervical Cancer Treatment Program (BCCTP) Application Guide

Breast and Cervical Cancer Treatment Program (BCCTP) Application Guide Breast and Cervical Cancer Treatment Program (BCCTP) Application Guide 2012 Created January 1, 2012 BCCTP APPLICATION GUIDE Table of Contents Page Application Process 3 Application Checklist 4 Federal

More information

Physical Exam Checklist

Physical Exam Checklist 1021 West 14 th Street P. O. Box 968 Hastings, Nebraska 68902-0968 Appointments (402) 463-2423 Business (402) 462-8456 Fax (402) 463-9698 Physical Exam Checklist This information is being sent to you for

More information

Progress in Cervical Screening in the UK

Progress in Cervical Screening in the UK Progress in Cervical Screening in the UK March 2016 Progress in Cervical Screening in the UK 1. Introduction Cervical cancer prevention has been based on cervical cytology screening for the last 50 years.

More information

Cervical Cancer Prevention and Early Detection What is cervical cancer?

Cervical Cancer Prevention and Early Detection What is cervical cancer? Cervical Cancer Prevention and Early Detection What is cervical cancer? Cervical cancer starts in cells lining the cervix. The cervix is the lower part of the uterus (womb). It is sometimes called the

More information

cancer cervical What women should know about and the human papilloma virus

cancer cervical What women should know about and the human papilloma virus What women should know about cervical cancer and the human papilloma virus American Cancer Society Guidelines for the Early Detection of Cervical Cancer I take care of myself so I can take care of my family.

More information

The Cervical Screening Manual

The Cervical Screening Manual The Cervical Screening Manual A Guide for Health Departments and Providers Collaboration Partners: Chronic Disease and Injury Section Breast and Cervical Cancer Control Program Women s and Children s Health

More information

WHO GUIDANCE NOTE. Comprehensive cervical cancer prevention and control: a healthier future for girls and women

WHO GUIDANCE NOTE. Comprehensive cervical cancer prevention and control: a healthier future for girls and women WHO GUIDANCE NOTE Comprehensive cervical cancer prevention and control: a healthier future for girls and women WHO Library Cataloguing-in-Publication Data WHO guidance note: comprehensive cervical cancer

More information

Screening for Cancer in Light of New Guidelines and Controversies. Christopher Celio, MD St. Jude Heritage Medical Group

Screening for Cancer in Light of New Guidelines and Controversies. Christopher Celio, MD St. Jude Heritage Medical Group Screening for Cancer in Light of New Guidelines and Controversies Christopher Celio, MD St. Jude Heritage Medical Group Screening Tests The 2 major objectives of a good screening program are: (1) detection

More information

PREVENTIVE HEALTHCARE GUIDELINES INTRODUCTION

PREVENTIVE HEALTHCARE GUIDELINES INTRODUCTION PREVENTIVE HEALTHCARE GUIDELINES INTRODUCTION Health Plan of Nevada and Sierra Health and Life suggest that health plan members get certain screening tests, exams and shots to stay healthy. This document

More information

FocalPoint guided screening

FocalPoint guided screening FocalPoint guided screening John-Paul BOGERS Ina Benoy Christophe Depuydt University of Antwerp Labo Lokeren campus Riatol - Antwerp - Overview What is focal point guided screening Technical introduction

More information

Guidelines for. Quality Assurance in Cervical Screening. Second Edition

Guidelines for. Quality Assurance in Cervical Screening. Second Edition Guidelines for Assurance in Cervical Screening Second Edition Guidelines for Assurance in Cervical Screening Second Edition Contents Foreword 6 Preface 7 Authors and contributors 8 Chapter 1 Introduction

More information

Invasive Cervical Cancer. Kathleen M. Schmeler, MD Associate Professor Department of Gynecologic Oncology

Invasive Cervical Cancer. Kathleen M. Schmeler, MD Associate Professor Department of Gynecologic Oncology Invasive Cervical Cancer Kathleen M. Schmeler, MD Associate Professor Department of Gynecologic Oncology Cervical Cancer Etiology Human Papilloma Virus (HPV): Detected in 99.7% of cervical cancers Cancer

More information

William Atkinson, MD, MPH Hepatitis B Vaccine Issues June 16, 2016

William Atkinson, MD, MPH Hepatitis B Vaccine Issues June 16, 2016 William Atkinson, MD, MPH Hepatitis B Vaccine Issues June 16, 2016 Advisory Committee on Immunization Practices (ACIP) The recommendations to be discussed are primarily those of the ACIP composed of 15

More information

Guidelines for. Quality Assurance in Cervical Screening. Second Edition

Guidelines for. Quality Assurance in Cervical Screening. Second Edition Guidelines for Assurance in Cervical Screening Second Edition Chapter 4 assurance in cytopathology 4.1 Introduction 4.2 s and standards in cytopathology 4.2.1 Organisational s 4.2.2 Laboratory facilities

More information

GUIDE BOOK FOR PROGRAMME HUBS AND SCREENING CENTRES. NHS Bowel Cancer Screening Programme Version 3 31 March 2008

GUIDE BOOK FOR PROGRAMME HUBS AND SCREENING CENTRES. NHS Bowel Cancer Screening Programme Version 3 31 March 2008 GUIDE BOOK FOR PROGRAMME HUBS AND SCREENING CENTRES NHS Bowel Cancer Screening Programme Version 3 31 March 2008 PREFACE ACKNOWLEDGEMENTS FURTHER INFORMATION 1. PROGRAMME OVERVIEW 1.1 Background 1 1.2

More information

Abnormal Pap Smear Tracking in General Internal Medicine Clinic

Abnormal Pap Smear Tracking in General Internal Medicine Clinic Abnormal Pap Smear Tracking in General Internal Medicine Clinic J A C O B K U R L A N D E R & T A R A O B R I E N C A R Q I P R O J E C T J A N U A R Y 2 0, 2 0 1 0 PDSA cycle Plan Act Do Study Our Charge

More information

Innersense Voice 139 Jan 15, 2013 Screen to Prevent: Cervical & Prostate Cancer

Innersense Voice 139 Jan 15, 2013 Screen to Prevent: Cervical & Prostate Cancer Screening test to detect cancer at its earliest stage has been one of the most studied areas in our fight against cancer. However, the benefits of screening in terms of cancer prevention, early detection

More information

Management of Abnormal Pap Smear Clinical Practice Guideline

Management of Abnormal Pap Smear Clinical Practice Guideline Management of Abnormal Pap Smear Clinical Guideline General Principles: The Papanicolaou (Pap) smear is widely credited with reducing mortality from cervical cancer, and remains the single best method

More information

Preventive Services for Pregnancy SERVICE WHAT IS COVERED INTERVALS OF COVERAGE Anemia Screening Screening Annual screening for pregnant women

Preventive Services for Pregnancy SERVICE WHAT IS COVERED INTERVALS OF COVERAGE Anemia Screening Screening Annual screening for pregnant women Preventive Services for Pregnancy SERVICE WHAT IS COVERED INTERVALS OF COVERAGE Anemia Annual screening for pregnant women Bacteriuria For pregnant women at 12-16 weeks gestation or first prenatal visit

More information

The Diagnosis of Cancer in the Pathology Laboratory

The Diagnosis of Cancer in the Pathology Laboratory The Diagnosis of Cancer in the Pathology Laboratory Dr Edward Sheffield Christmas Select 74 Meeting, Queen s Hotel Cheltenham, 3 rd December 2014 Agenda Overview of the pathology of cancer How specimens

More information

Understanding. Cervical Changes A Health Guide for Women. National Cancer Institute U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES

Understanding. Cervical Changes A Health Guide for Women. National Cancer Institute U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES National Cancer Institute Understanding Cervical Changes A Health Guide for Women U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health This guide helped me talk with my doctor after

More information

NOTTINGHAM UNIVERSITY HOSPITAL NHS TRUST NOTTINGHAM BREAST INSTITUTE BREAST AND OVARIAN FAMILY HISTORY GUIDELINES

NOTTINGHAM UNIVERSITY HOSPITAL NHS TRUST NOTTINGHAM BREAST INSTITUTE BREAST AND OVARIAN FAMILY HISTORY GUIDELINES NOTTINGHAM UNIVERSITY HOSPITAL NHS TRUST NOTTINGHAM BREAST INSTITUTE BREAST AND OVARIAN FAMILY HISTORY GUIDELINES GP Referrals All GP referrals for asymptomatic women with a family history of breast and/or

More information

A Cost Effectiveness Analysis of Cervical Cancer Screening in Sweden

A Cost Effectiveness Analysis of Cervical Cancer Screening in Sweden A Cost Effectiveness Analysis of Cervical Cancer Screening in Sweden Abstract The thesis deals with the problem of how to effectively minimize the prevalence of cervical cancer in Sweden. A cost effectiveness

More information

CERVICAL CANCER SCREENING

CERVICAL CANCER SCREENING CERVICAL CANCER SCREENING APPLICATIONS OBJECTIVE Purpose of Measure: ELIGIBLE POPULATION Which members are included? STANDARD OF CARE What screening should be done? NCQA ACCEPTED CODES DOCUMENTATION REQUIREMENTS

More information

SITUATIONAL ANALYSIS OF CERVICAL CANCER PREVENTION AND CONTROL IN THE CARIBBEAN

SITUATIONAL ANALYSIS OF CERVICAL CANCER PREVENTION AND CONTROL IN THE CARIBBEAN SITUATIONAL ANALYSIS OF CERVICAL CANCER PREVENTION AND CONTROL IN THE CARIBBEAN Results from a 2013 assessment of country policies and services for HPV vaccination, cervical cancer screening, diagnosis

More information

Abigail R. Proffer, M.D. October 4, 2013

Abigail R. Proffer, M.D. October 4, 2013 Abigail R. Proffer, M.D. October 4, 2013 Topics Human Papillomavirus (HPV) Vaccines Pap smears Colposcopy Contraception Polycystic Ovary Syndrome (PCOS) Can I get pregnant? Miscarriage Abnormal Uterine

More information

Students receiving the HPV vaccine (Gardasil) in Catholic schools

Students receiving the HPV vaccine (Gardasil) in Catholic schools Students receiving the HPV vaccine (Gardasil) in Catholic schools The Calgary Catholic School District Board of Trustees passed the following motion at its regularly scheduled public board meeting held

More information

Information about hepatitis C for patients and carers

Information about hepatitis C for patients and carers Information about hepatitis C for patients and carers What is hepatitis C? Hepatitis C is an illness caused by a virus which can be passed through blood from one person to another. It mainly affects the

More information

Interim Guidance for Medical Schools on health checks for active and latent Tuberculosis in medical students returning from elective periods overseas

Interim Guidance for Medical Schools on health checks for active and latent Tuberculosis in medical students returning from elective periods overseas Interim Guidance for Medical Schools on health checks for active and latent Tuberculosis in medical students returning from elective periods overseas This document has been developed by: Dr Mathina Darmalingam

More information

OREGON HEALTH AUTHORITY IMMUNIZATION PROTOCOL FOR PHARMACISTS Human Papilloma Virus Vaccines (HPV)

OREGON HEALTH AUTHORITY IMMUNIZATION PROTOCOL FOR PHARMACISTS Human Papilloma Virus Vaccines (HPV) OREGON HEALTH AUTHORITY IMMUNIZATION PROTOCOL FOR PHARMACISTS Human Papilloma Virus Vaccines (HPV) Revisions as of 01-01-2016 Vaccination age changed to clients 7 years of age Removal of adolescent well

More information

Ductal carcinoma in situ (DCIS)

Ductal carcinoma in situ (DCIS) DIAGNOSIS: DCIS Ductal carcinoma in situ (DCIS) This factsheet gives information on an early form of breast cancer called ductal carcinoma in situ (DCIS). It explains what it is, how your breast is made

More information